TY - JOUR
T1 - South American Hemorrhagic Fevers
T2 - A summary for clinicians
AU - On behalf of the members of the Medical Countermeasures Working Group of the National Emerging Special Pathogens Training and Education Center's (NETEC's) Special Pathogens Research Network (SPRN)
AU - Frank, Maria G.
AU - Beitscher, Adam
AU - Webb, Camille M.
AU - Raabe, Vanessa
AU - Bhadelia, Nahid
AU - Cieslak, Theodore J.
AU - Davey, Richard T.
AU - Dierberg, Kerry
AU - Evans, Jared D.
AU - Grein, Jonathan
AU - Kortepeter, Mark G.
AU - Kraft, Colleen S.
AU - Kratochvil, Chris J.
AU - Martins, Karen
AU - McLellan, Susan
AU - Mehta, Aneesh K.
AU - Risi, George
AU - Sauer, Lauren
AU - Shenoy, Erica S.
AU - Uyeki, Tim
N1 - Publisher Copyright:
© 2021 The Author(s)
PY - 2021/4
Y1 - 2021/4
N2 - Objectives: This article is one of a series on acute, severe diseases of humans caused by emerging viruses for which there are no or limited licensed medical countermeasures. We approached this summary on South American Hemorrhagic Fevers (SAHF) from a clinical perspective that focuses on pathogenesis, clinical features, and diagnostics with an emphasis on therapies and vaccines that have demonstrated potential for use in an emergency situation through their evaluation in nonhuman primates (NHPs) and/or in humans. Methods: A standardized literature review was conducted on the clinical, pathological, vaccine, and treatment factors for SAHF as a group and for each individual virus/disease. Results: We identified 2 treatments and 1 vaccine platform that have demonstrated potential benefit for treating or preventing infection in humans and 4 other potential treatments currently under investigation. Conclusion: We provide succinct summaries of these countermeasures to give the busy clinician a head start in reviewing the literature if faced with a patient with South American Hemorrhagic Fever. We also provide links to other authoritative sources of information.
AB - Objectives: This article is one of a series on acute, severe diseases of humans caused by emerging viruses for which there are no or limited licensed medical countermeasures. We approached this summary on South American Hemorrhagic Fevers (SAHF) from a clinical perspective that focuses on pathogenesis, clinical features, and diagnostics with an emphasis on therapies and vaccines that have demonstrated potential for use in an emergency situation through their evaluation in nonhuman primates (NHPs) and/or in humans. Methods: A standardized literature review was conducted on the clinical, pathological, vaccine, and treatment factors for SAHF as a group and for each individual virus/disease. Results: We identified 2 treatments and 1 vaccine platform that have demonstrated potential benefit for treating or preventing infection in humans and 4 other potential treatments currently under investigation. Conclusion: We provide succinct summaries of these countermeasures to give the busy clinician a head start in reviewing the literature if faced with a patient with South American Hemorrhagic Fever. We also provide links to other authoritative sources of information.
KW - Argentine hemorrhagic fever
KW - Bolivian hemorrhagic fever
KW - Brazilian hemorrhagic fever
KW - Junín virus
KW - Machupo virus
KW - New World Arenavirus
KW - South American hemorrhagic fevers
KW - Venezuelan hemorrhagic fever
UR - http://www.scopus.com/inward/record.url?scp=85105833876&partnerID=8YFLogxK
U2 - 10.1016/j.ijid.2021.02.046
DO - 10.1016/j.ijid.2021.02.046
M3 - Review article
C2 - 33610781
AN - SCOPUS:85105833876
SN - 1201-9712
VL - 105
SP - 505
EP - 515
JO - International Journal of Infectious Diseases
JF - International Journal of Infectious Diseases
ER -